Laboratorios Farmaceuticos Rovi, S.A. (BIT:1ROVI)

Market Cap	2.76B
Revenue (ttm)	767.47M
Net Income (ttm)	140.02M
Shares Out	n/a
EPS (ttm)	2.74
PE Ratio	19.73
Forward PE	19.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	52.10
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
RSI	56.32
Earnings Date	May 9, 2025

About BIT:1ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ROVI

Financial Performance

In 2024, BIT:1ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.